Alzheimer's disease (AD) biomarkers have revolutionized our understanding of disease pathophysiology and have become essential for diagnosis, prognosis, and clinical trial enrollment. The ATN (Amyloid, Tau, Neurodegeneration) framework, introduced in 2018, provides a comprehensive classification system that maps biomarkers to specific pathological mechanisms . This page explores the mechanistic basis of established and emerging AD biomarkers, connecting biomarker changes to specific molecular and cellular processes in neurodegeneration .
The development of biomarkers for AD reflects decades of research into the disease's core pathological features: amyloid-beta (Aβ) plaque accumulation, tau neurofibrillary tangle formation, synaptic dysfunction, and neuronal loss. Each biomarker provides window into different aspects of disease pathogenesis, enabling a more precise characterization of disease stage and progression .
Amyloid-beta peptide is generated through sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase. The Aβ species most prone to aggregation, particularly Aβ42, oligomerizes and forms insoluble plaques in the brain parenchyma .
APP Processing Pathways:
- Amyloidogenic pathway: APP → BACE → Aβ peptides
- Non-amyloidogenic pathway: α-secretase → sAPPα, CTFα → AICD
The amyloid cascade hypothesis proposes that Aβ accumulation triggers a pathogenic cascade leading to tau pathology, synaptic dysfunction, and neuronal death. While recent clinical trials have questioned the linear cascade model, amyloid remains a defining feature of AD pathophysiology .
Tau protein is a microtubule-associated protein that stabilizes neuronal cytoskeleton. In AD, hyperphosphorylated tau dissociates from microtubules and forms paired helical filaments (PHFs) that aggregate into neurofibrillary tangles (NFTs) .
Tau Phosphorylation Sites: Over 40 phosphorylation sites have been identified on tau, with key sites including:
- Ser202/Thr205 (AT8 epitope)
- Thr231 (AT180 epitope)
- Ser396/Ser404 (PHF-1 epitope)
The spread of tau pathology follows a characteristic pattern correlating with clinical progression, beginning in the entorhinal cortex and spreading to limbic structures and neocortical areas .
Neurodegeneration in AD manifests as synaptic loss, neuronal death, and brain atrophy. Multiple mechanisms contribute to neurodegeneration:
- Excitotoxicity from glutamate dysregulation
- Oxidative stress and mitochondrial dysfunction
- Neuroinflammation mediated by activated microglia
- Calcium dysregulation
- Apoptotic and necroptotic cell death pathways
¶ Biomarker Categories and Mechanistic Mapping
¶ CSF Aβ42 and Aβ40
Measurement: CSF Aβ42 and Aβ40 are quantified using immunoassays (ELISA, SIMOA). The Aβ42/Aβ40 ratio has emerged as a more sensitive marker than Aβ42 alone.
Mechanistic Interpretation:
- Reduced CSF Aβ42 reflects decreased brain-to-CSF efflux due to plaque retention
- Aβ42 is preferentially deposited in plaques compared to Aβ40
- The ratio normalizes for inter-individual variation in APP metabolism
- Approximately 30-50% reduction in CSF Aβ42 in AD patients
Threshold: Optimal diagnostic cutoff varies by assay but typically:
- Aβ42 < 500 pg/mL suggests amyloid positivity
- Aβ42/Aβ40 ratio < 0.06-0.08 indicates amyloid pathology
Tracers: ¹¹C-Pittsburgh Compound-B (PiB), ¹⁸F-florbetapir (Amyvid), ¹⁸F-florbetaben (Neuraceq), ¹⁸F-AZD4694
Mechanistic Interpretation:
- PET ligands bind to fibrillar Aβ plaques
- Signal reflects plaque density in cortical and subcortical regions
- Positivity typically precedes clinical symptoms by 10-20 years
- Good correlation with post-mortem plaque burden
Standardized Uptake Value Ratio (SUVR):
- Composite SUVR > 1.2-1.4 typically indicates amyloid positivity
- Regional patterns: precuneus, posterior cingulate, lateral parietal
Measurement: CSF t-tau measured via immunoassay reflects tau release from degenerating neurons.
Mechanistic Interpretation:
- Elevated t-tau indicates neuronal damage and death
- Levels correlate with the severity of neurodegeneration
- Increases 2-3 fold in AD compared to controls
- Less specific than p-tau, as elevated in other dementias and stroke
Clinical Utility:
- Supports AD diagnosis when elevated
- Prognostic value for cognitive decline
- Higher levels associated with more rapid progression
Measurement: p-tau isoforms (p-tau181, p-tau217, p-tau231) measured using phosphorylation-specific antibodies.
Mechanistic Interpretation:
- p-tau181: Most widely validated, reflects early tau pathology
- p-tau217: Higher diagnostic accuracy, correlates with Thal amyloid phase
- p-tau231: Earliest detectable change, reflects pretangle pathology
Specificity:
- p-tau is highly specific for AD (>90%)
- Does not significantly elevate in other tauopathies (PSP, CBD)
- Direct reflection of tau kinase/phosphatase activity
Threshold Examples:
- p-tau181 > 60 pg/mL indicates tau pathology
- p-tau217 > 0.8 pg/mL (depending on assay)
Tracers: ¹⁸F-AV-1451 (Flortaucipir), ¹⁸F-GT-1, ¹⁸F-RK-311
Mechanistic Interpretation:
- Binds to neurofibrillary tangles (PHFs)
- Signal correlates with Braak staging
- Regional pattern follows characteristic AD progression
- Limited binding to diffuse tau or astrocytes
Clinical Correlations:
- Stronger correlation with cognitive impairment than amyloid
- Predicts future cognitive decline
- Differentiates AD from other dementias
Measurement: NfL quantified using ultra-sensitive Simoa or ELISA assays.
Mechanistic Interpretation:
- NfL is released during axonal damage
- Reflects the rate of axonal degeneration
- Elevates in AD, but also in other neurodegenerative conditions
- More pronounced elevation in faster-progressing patients
Clinical Utility:
- Prognostic marker for disease progression
- Monitors treatment response in clinical trials
- Differentiates AD from FTD when combined with other markers
Measurement: Neurogranin is a dendritic protein measured in CSF as a marker of synaptic dysfunction.
Mechanistic Interpretation:
- Loss of neurogranin indicates dendritic spine loss
- Early marker of synaptic pathology
- Elevated in AD even in prodromal stages
- Correlates with cognitive impairment
Measurement: Fluorodeoxyglucose (FDG) PET measures cerebral glucose metabolism.
Mechanistic Interpretation:
- Hypometabolism reflects synaptic dysfunction and neuronal loss
- Characteristic pattern: posterior cingulate, precuneus, lateral parietal
- Correlates with severity of cognitive impairment
- Precedes atrophy on structural MRI
Typical Findings:
- Posterior cingulate SUVR < 0.85 suggests AD
- Predictive of progression from MCI to AD
Measurement: Volumetric MRI measures hippocampal volume, cortical thickness, and ventricular enlargement.
Mechanistic Interpretation:
- Hippocampal atrophy reflects neurodegeneration
- Regional patterns indicate disease stage
- Annual atrophy rate ~1-2% in AD vs. 0.2-0.5% in controls
- Medial temporal lobe earliest affected
Biomarker Thresholds:
- Hippocampal volume < 6000 mm³ suggests significant atrophy
- Cortical thickness reduction > 0.3 mm/year concerning
| Biomarker |
Source |
Mechanism |
AD Specificity |
| Synaptotagmin-1 |
CSF |
Presynaptic loss |
Moderate |
| Synapsin-1 |
CSF |
Synaptic integrity |
Moderate |
| SNAP-25 |
CSF |
Presynaptic terminal |
Moderate |
| GAP-43 |
CSF |
Axonal sprouting |
Low |
CSF Markers:
- YKL-40 (chitinase-3-like protein 1): Microglial activation
- TREM2: Triggering receptor on myeloid cells 2
- IL-6, IL-1β, TNF-α: Pro-inflammatory cytokines
- S100B: Astrocytic activation
PET Markers:
- ¹¹C-PK11195: TSPO binding for microglial activation
- ¹⁸F-GE-180: Second-generation TSPO tracer
Blood-based biomarkers represent a major advance for AD diagnosis:
Aβ Species:
- Aβ42/Aβ40 ratio in plasma (Ultra-sensitive immunoassays)
- Plasma p-tau217 shows excellent performance
- Simoa and other platforms enabling pg/mL sensitivity
p-tau in Blood:
- p-tau181: FDA-approved for AD diagnosis
- p-tau217: Highest diagnostic accuracy
- p-tau231: Early detection
NfL in Blood:
- Elevated in AD and other neurodegenerative diseases
- Good correlation with CSF NfL
- Useful for disease monitoring
Risk Genes:
- APOE ε4: Strongest risk factor
- TREM2: Microglial dysfunction
- CLU, PICALM, CR1: Synaptic function
Causal Genes (Autosomal Dominant AD):
- APP, PSEN1, PSEN2: Mutations cause early-onset AD
The ATN framework provides a standardized approach to biomarker interpretation :
| Category |
Biomarker Type |
Example |
Reflects |
| A |
Core |
CSF Aβ42, PET amyloid |
Amyloid pathology |
| T |
Core |
CSF p-tau, PET tau |
Tau pathology |
| N |
Core |
FDG-PET, MRI, CSF NfL |
Neurodegeneration |
- Normal ATN: A-T-N- (cognitively normal)
- Alzheimer's continuum: A+T+(N+ or N-)
- Alzheimer's disease: A+T+N+
- Non-AD dementia: A-T-N+
This framework enables:
- Accurate diagnosis in early disease stages
- Differentiation of AD from other dementias
- Enrichment of clinical trials
- Monitoring of disease progression
- Amyloid PET positive 10-20 years before symptoms
- CSF Aβ42 reduced 10-15 years before symptoms
- p-tau may begin to elevate 5-10 years before symptoms
- FDG-PET and MRI typically normal
- Progressive amyloid accumulation
- Emerging tau pathology in limbic regions
- Subtle hypometabolism in posterior cingulate
- Mild hippocampal atrophy begins
- Plateau in amyloid burden
- Progressive tau spread to neocortex
- Significant hypometabolism
- Accelerated brain atrophy
NIA-AA Criteria (2018):
- Requires biomarker evidence for AD pathophysiology
- Supports diagnosis in uncertain cases
- Enables earlier diagnosis in preclinical stages
Biomarker Combinations for Diagnosis:
| Clinical Scenario |
Recommended Biomarkers |
| Typical AD |
Amyloid PET + tau PET |
| Atypical presentation |
CSF t-tau/p-tau + MRI |
| Research enrollment |
CSF Aβ42/40 + p-tau181 |
| Primary care screening |
Plasma p-tau217 |
Progression Markers:
- NfL: Rate of progression
- p-tau: Tau spread
- MRI atrophy rate: Neurodegeneration pace
Predictive Value:
- Elevated NfL predicts rapid decline
- Higher p-tau correlates with faster progression
- Combined biomarkers improve predictive accuracy
Biomarker-Based Selection:
- Amyloid positivity required for anti-amyloid trials
- Tau positivity for anti-tau trials
- Baseline NfL for progression-focused trials
Endpoint Biomarkers:
- CSF/Plasma p-tau as treatment response marker
- MRI atrophy as structural endpoint
- FDG-PET for metabolic response
AD biomarker-to-mechanism mapping connects with numerous pathways:
The relationship between amyloid and tau pathology is complex and bidirectional. Several biomarkers reflect this interaction:
Soluble Aβ-Tau Complexes:
- CSF contains soluble complexes of Aβ and tau
- These complexes may be more toxic than either alone
- Detection methods using co-immunoprecipitation show AD-specific patterns
- Correlates with cognitive decline better than either marker alone
Aβ-Induced Tau Phosphorylation:
- Aβ exposure activates several tau kinases (GSK3β, CDK5)
- Biomarkers of kinase activity can be measured in CSF
- p-tau/t-tau ratio indicates pathological phosphorylation
- Anti-amyloid treatment can reduce p-tau in some patients
Tau Secretion Mechanisms:
- Tau is released via multiple pathways (exosomes, ectosomes, direct release)
- Secretion is activity-dependent and increases with neuronal activity
- Oligomeric tau is more readily secreted than monomeric tau
- Secreted tau may propagate pathology between neurons
TREM2 and Disease Progression:
- TREM2 is expressed on microglia
- CSF TREM2 reflects microglial activation
- Elevated in early AD, then declines with progression
- TREM2 variants affect AD risk and biomarker trajectories
Complement System Activation:
- C1q, C3, C4 fragments in CSF
- Indicates synaptic pruning by microglia
- Elevated in AD and correlates with cognitive decline
- Potential therapeutic target
Glial Fibrillary Acidic Protein (GFAP):
- Astrocytic activation marker
- Blood-based biomarker showing promise
- Elevates early in AD pathogenesis
- Reflects astrocyte reactivity to amyloid deposition
Multi-Marker Synaptic Panels:
- Combining neurogranin, synaptotagmin, SNAP-25 provides comprehensive view
- Each marker reflects different aspect of synaptic pathology
- Patterns differ between AD and other dementias
- Useful for differential diagnosis
Electrophysiological Biomarkers:
- EEG/MEG as functional synaptic markers
- Slowing of background rhythm in AD
- Event-related potentials affected
- Auditory mismatch negativity predicts progression
Decade-Long Natural History:
| Years Before Onset |
Biomarker Changes |
| 20+ |
CSF Aβ42 begins to decline |
| 15-20 |
Amyloid PET becomes positive |
| 10-15 |
CSF p-tau begins to elevate |
| 5-10 |
Subtle FDG-PET changes emerge |
| 3-5 |
CSF NfL begins rising, hippocampal atrophy begins |
| 1-3 |
Clinical symptoms emerge (MCI) |
| 0 |
Dementia diagnosis possible |
Rate of Change Metrics:
- Annual change in hippocampal volume: critical for progression
- CSF p-tau trajectory: indicates tau spreading
- NfL rate of change: most powerful progression marker
- Amyloid PET centiloid change: plateau in established AD
Diagnostic Algorithms:
- Primary screening: plasma p-tau217
- Confirmatory: CSF Aβ42/40 ratio
- Staging: CSF p-tau181, NfL
- Prognosis: longitudinal MRI, NfL trajectory
Personalized Biomarker Panels:
- Based on genetic risk (APOE status)
- Family history considerations
- Age of onset
- Clinical presentation
¶ Assay Standardization
Reference Materials:
- WHO International Standard for CSF tau (IS 07/396)
- Certified reference materials for Aβ42
- Efforts to harmonize across platforms
Quality Control:
- Internal QC pools for each run
- Between-run coefficients of variation <10%
- External quality assessment programs
- Sample handling protocols critical
Collection Factors:
- Collection tubes: polypropylene recommended
- Centrifugation: 2000 × g for 10 minutes
- Aliquoting: within 1 hour of collection
- Storage: -80°C, avoid freeze-thaw cycles
CSF Characteristics:
- Blood contamination affects results
- Opening pressure should be documented
- Volume consistency important
- Time of day may affect some markers
Confounding Conditions:
- Renal dysfunction affects NfL
- Age-related changes in baseline
- Comorbid neurological conditions
- Medication effects
Population-Specific Considerations:
- APOE ε4 carriers have lower CSF Aβ42
- Sex differences in some biomarkers
- Education effects on cognitive testing
- Cultural factors in biomarker interpretation
Novel Tau Species:
- CSF tau oligomers: direct detection of toxic species
- MTBR-tau fragments: specific to tangles
- Tau kinase activity markers
- Exosomal tau: brain-origin specific
Synaptic Imaging:
- SV2A PET ligands: synaptic density
- Synaptic vesicle proteins as targets
- Preclinical validation ongoing
Blood-Based Advances:
- Exosome-based biomarkers
- Brain-derived vesicle isolation
- Multi-analyte panels
- Point-of-care platforms
¶ Regulatory Status and Clinical Implementation
FDA-Approved Biomarkers:
- Amyloid PET tracers (florbetapir, florbetaben, flutemetamol): FDA approved for clinical use
- CSF biomarkers (Aβ42, t-tau, p-tau181): CLIA-certified laboratory developed tests
- Plasma p-tau217: FDA approved in 2025
Clinical Practice Guidelines:
- AAT framework integrated into 2024 AAIC recommendations
- Blood-based biomarkers recommended for screening
- CSF biomarkers remain gold standard for research
Reimbursement Status:
- Amyloid PET: covered for appropriate clinical scenarios
- CSF biomarkers: variable coverage
- Plasma biomarkers: emerging coverage
Early AD (MCI):
- Hippocampal atrophy: 10-20% volume loss
- Entorhinal cortex thinning
- Posterior cingulate volume reduction
- Relative preservation of primary sensory cortex
Moderate AD:
- Progressive hippocampal atrophy: 20-30% loss
- Temporal pole involvement
- Parietal lobe changes prominent
- Beginning of ventricular enlargement
Severe AD:
- Diffuse cortical atrophy
- Severe hippocampal volume loss (>30%)
- Significant ventricular dilation
- Frontal lobe involvement
Amyloid PET Progression:
- Initial: posterior cingulate, precuneus
- Progression: lateral parietal, prefrontal
- Later: occipital, motor cortex
- Plateau in moderate-to-severe disease
Tau PET Patterns:
- Braak I-II: entorhinal cortex
- Braak III-IV: limbic (hippocampus, amygdala)
- Braak V-VI: isocortical (prefrontal, parietal)
- Stronger cognitive correlation than amyloid
¶ Biomarker Concordance and Discordance
Concordant Patterns (Typical AD):
- Amyloid PET positive + CSF Aβ42 reduced
- Tau PET positive + CSF p-tau elevated
- FDG-PET hypometabolism + structural atrophy
Discordant Patterns:
- Amyloid positive + Tau negative: preclinical AD
- Amyloid negative + Tau positive: suspected non-AD tauopathy
- Tau positive + Neurodegeneration negative: early AD
- Biomarker negative + clinical symptoms: possible FTD or other
Clinical Implications:
- Discordance requires careful interpretation
- May indicate mixed pathology
- Influences treatment decisions
- Affects prognosis
Digital Biomarkers:
- Smartphone-based cognitive testing
- Wearable sensor movement analysis
- Voice analysis for language changes
- Sleep pattern monitoring
Multi-Omics Integration:
- Genomics + proteomics + metabolomics
- Machine learning for pattern recognition
- Personalized biomarker signatures
- Integration with electronic health records
¶ Clinical Translation and Therapeutic Implications
¶ Current Therapeutic Landscape
AD biomarkers enable precision medicine approaches in clinical practice:
- Patient stratification by amyloid/tau status ensures mechanistic targeting
- Enrichment strategies select for rapid progressors or specific subtypes
- Biomarker-based endpoints enable earlier readouts vs. clinical measures
- Personalized treatment selection based on individual biomarker profiles
Current FDA-approved treatments with biomarker correlates:
| Drug |
Mechanism |
Key Biomarker Changes |
| Lecanemab (Leqembi) |
Anti-Aβ protofibril |
Reduced plasma p-tau217, decreased amyloid PET |
| Donanemab (Kisunla) |
Anti-amyloid plaque |
Decreased plasma p-tau217, reduced amyloid PET |
| Aducanumab (Aduhelm) |
Anti-Aβ plaques |
Lower CSF Aβ42, reduced amyloid PET |
The identified ion channel mechanisms represent promising therapeutic targets:
| Ion Channel |
Therapeutic Approach |
Biomarker Strategy |
| VGCC (L-type) |
Calcium channel modulators |
Use p-tau and NfL as response markers |
| Sodium channels |
Nav1.x inhibitors |
Monitor cortical hyperexcitability via EEG |
| Potassium channels |
Kv channel openers |
Track synaptic function via CSF biomarkers |
| P2X7 receptor |
P2X7 antagonists |
Measure neuroinflammation via IL-1β, TREM2 |
| TRPM2/TRPV1 |
Channel blockers |
Assess oxidative stress markers |
Biomarkers validate drug target engagement in real-time:
- CSF Aβ42 confirms anti-amyloid mechanism
- p-tau species assess anti-tau effects
- NfL indicates neuroprotective benefit
- Neurofilament light tracks disease modification
Multi-target approaches guided by biomarker profiles:
- Amyloid removal + neuroprotection (NfL monitoring)
- Tau reduction + synaptic repair (synaptic biomarkers)
- Neuroinflammation control + neurodegeneration prevention
Active and recent AD biomarker clinical trials:
| Trial ID |
Agent |
Target |
Phase |
Status |
Biomarker Focus |
| NCT05360472 |
Donanemab |
Amyloid plaque |
Phase 3 |
Active |
Amyloid PET, p-tau217, NfL |
| NCT04468603 |
Lecanemab |
Aβ protofibrils |
Phase 3 |
Completed |
Plasma p-tau217, amyloid PET |
| NCT04623216 |
Semorinemab |
Tau |
Phase 2 |
Completed |
CSF p-tau, tau PET |
| NCT05498661 |
E2814 |
p-tau217 |
Phase 2/III |
Recruiting |
p-tau217, tau PET |
| NCT04868214 |
Gosuranemab |
Tau |
Phase 2 |
Completed |
CSF p-tau181 |
| NCT03845694 |
Azeliragon |
RAGE |
Phase 3 |
Completed |
CSF biomarkers, FDG-PET |
AD biomarker-to-therapeutic connections:
- Amyloid biomarkers (CSF Aβ42, PET amyloid): Select patients for anti-amyloid therapies
- Tau biomarkers (p-tau181, p-tau217, tau PET): Monitor anti-tau treatment response
- Neurodegeneration biomarkers (NfL, MRI, FDG-PET): Assess disease modification
- Neuroinflammation biomarkers (TREM2, YKL-40, TSPO PET): Guide immunomodulatory approaches
- Synaptic biomarkers (neurogranin, SNAP-25): Track synaptic repair
Biomarker-driven clinical impact:
- Earlier diagnosis: Preclinical AD identification enables timely intervention
- Personalized treatment selection: Biomarker profiles guide therapy choice
- Prognostic counseling: Biomarker trajectories inform disease progression expectations
- Trial eligibility: Biomarker-based enrichment increases access to experimental therapies
- Monitoring treatment response: Longitudinal biomarker changes track therapeutic efficacy
Clinical Implementation Challenges:
- Assay standardization across platforms
- Cost and accessibility of advanced biomarkers
- Interpretation complexity in clinical settings
- Integration with clinical decision-making
- Blood-based biomarker adoption: Plasma p-tau217 for widespread screening
- Multi-modal biomarker panels: Integrated diagnostic algorithms
- Digital biomarkers: AI-powered cognitive assessment integration
- Personalized biomarker thresholds: Individual baseline-adjusted cutoffs
AD biomarkers provide essential mechanistic insight into disease pathophysiology, enabling accurate diagnosis, prognosis, and clinical trial design. The ATN framework offers a standardized approach to integrate biomarker information for clinical and research applications. The emergence of blood-based biomarkers promises to democratize access to accurate AD diagnosis and monitoring. Understanding the mechanistic basis of each biomarker remains essential for proper interpretation and clinical application.